Premium
Identification of DNA methylation signature to predict prognosis in gastric adenocarcinoma
Author(s) -
Hu Sifeng,
Yin Xiankun,
Zhang Guangyong,
Meng Fanmei
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.28450
Subject(s) - dna methylation , methylation , adenocarcinoma , proportional hazards model , gene signature , cancer , oncology , medicine , survival analysis , biology , carcinogenesis , gene , genetics , gene expression
Gastric adenocarcinoma is an important death‐related cancer. To find factors related to survival and prognosis, and thus improve recovery prospects, a powerful signature is needed. DNA methylation plays an important role in gastric adenocarcinoma processes and development, and here we report on the search for a significant DNA methylation gene to aid with the earlier diagnosis of gastric adenocarcinoma patients. A Cox proportional risk regression analysis and random survival forest algorithm were used to analyze gastric adenocarcinoma patients’ DNA methylation data from The Cancer Genome Atlas, a public database. DNA methylation gene signature consisting of five genes ( SERPINA3, AP000357.4, GZMA, AC004702.2, and GREB1L ) were selected. As the most accurate predictor, the area under the curve in the training and test group were 0.72 and 0.61, respectively. The signature was able to sort patients into high‐ and low‐risk groups with meaningful overall survival rates (median: 18.36 vs 72.23 months, log‐rank test, P < 0.001) in the training group, which predictive ability was validated in a test data set (median: 25.56 vs 58.80 months, log‐rank test, P < 0.016). A multivariate Cox regression analysis showed the significant DNA methylation was an independent prediction prognostic factor for gastric adenocarcinoma patients. Functional analysis suggests that these signature genes may be related to pathways and biological processes associated with tumorigenesis. The significant DNA methylation gene could be a novel prediction and prognostic biomarker that both aids in the treatment and predicts the overall survival likelihoods of gastric adenocarcinoma patients.